Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 M{DNc2NmdGxiVnnhZoltcXS7IFHzd4F6 NFzuOnYzNjVvMUWgcm0> NF;EfIM4OiCq M3LJVYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M33CRVI2PzlyOUC3
U2932  M1rvPGNmdGxiVnnhZoltcXS7IFHzd4F6 NF\jVHAzNjVvMUWgcm0> MVW3NkBp NHO1e3NqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi M3PQTFI2PzlyOUC3
OCI-LY7 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MljyNk42NTF3IH7N NFiwZpY4OiCq MXHpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NU\YO4VSOjV5OUC5NFc>
Farage MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mof3Nk42NTF3IH7N NHjMNFE4OiCq NULCcZR3cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NWTMdWR6OjV5OUC5NFc>
LY7/EBV MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYCyMlUuOTVibl2= MlfjO|IhcA>? MnfBbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXiyOVc6ODlyNx?=
U2932/EBV MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVSyMlUuOTVibl2= NWPLfFI5PzJiaB?= MYjpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MVmyOVc6ODlyNx?=
HCT116 M4naXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[2OU02ODByIH7N MnnaNlQhcA>? NUDJd|BWTE2VTx?= NX\rXXdKcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz Mmq2NlU1QTJ3MUW=
ACH-2 NWHNVVhzTnWwY4Tpc44hSXO|YYm= NWHwdpVQOS17IH7N M3n4VVI1KGh? MULpcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u NUnQS4tLOjVzNEm0Olc>
MCF-10A M3HYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMUhCtVAvODFibl2= NFzFUlgzPDl3NEi1Oi=>
MCF-7 NIjjT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vycWlEPTB;MT6xNOKyOC5{MDDuUS=> M2TrWlI1QTV2OEW2
SK-BR-3 NF;MVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfNWHM3UUN3ME2xMlAxyrFyLkO1JI5O Ml[wNlQ6PTR6NU[=
MDA-MB-231 NUewVo5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rhTGlEPTB;MD62POKyOC5zNDDuUS=> M2Gze|I1QTV2OEW2
PC3 M1rtd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3tTWM2OD1zLk[1xtExNjN3IH7N M4\Ze|I1QTV2OEW2
HCT116 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HZWmlEPTB;MT6wNOKyOC5yMDDuUS=> M4fEPVI1QTV2OEW2
HCT116-p21-/- MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1na[2lEPTB;MT6yOuKyOC5|NzDuUS=> NYDmVXV6OjR7NUS4OVY>
S1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG3Om5KSzVyPUeuOlfDuTBwMkmgcm0> NGnHTWIzPDl3NEi1Oi=>
SW620 M{Hqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv4TWM2OD1yLkmzxtExNjJ7IH7N NVvKPZU4OjR7NUS4OVY>
LOX-IMVI NEHIfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwOEhCtVAvODNibl2= NG\TTnkzPDl3NEi1Oi=>
UACC-62 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3uPY9WUUN3ME2wMlU3yrFyLkG2JI5O MW[yOFk2PDh3Nh?=
MDA-MB-435 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP0Z5BKSzVyPUCuPVDDuTBwME[gcm0> NY\PT5pYOjR7NUS4OVY>
SF-295 M3:1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwOElCtVAvOTVibl2= MXqyOFk2PDh3Nh?=
A549 NWDJSmg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImzZpNKSzVyPUGuNlbDuTBwMkSgcm0> M2XORlI1QTV2OEW2
H460 NFH1eWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwNUlCtVAvQDBibl2= MnzZNlQ6PTR6NU[=
EKVX NHPoXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zDR2lEPTB;MT6zN:KyOC5|NDDuUS=> NVzQe3VLOjR7NUS4OVY>
H146 MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLy[4RpUUN3ME2wMlIzyrFyLkC3JI5O NHnTfVkzPDl3NEi1Oi=>
H526 NWGxR4ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMUZCtVAvODNibl2= MVGyOFk2PDh3Nh?=
HuT-78 NEO1Z2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XL[GlEPTB;MT63N:KyOC52NDDuUS=> NHLvPJgzPDl3NEi1Oi=>
HA MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV22coVsOC54MkWtNVBvVQ>? NXnlfY5EPDhiaB?= NHWyZolqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? NVW3RYp4OjR5N{G1NVA>
MS-275 M2HmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7RNE43OjVvMUDuUS=> NUjIWG1lPDhiaB?= MmjYbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MoDQNlQ4PzF3MUC=
CD4 T NXfMWphMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33nXVQ5KGh? NWOwUWQ6TUN3ME20MlXDuTFwMDDuUS=> NIO1WoszPDd{MkS1OC=>
CD4 T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe3dnI1QCCq NHTEeGNESzVyPUGwO:KyOTJ4IH7N M1;oSFI1PzJ{NEW0
CD4+ T MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDreZhGSzVyPUOgcm0> MnHGNlQ1QTVzMEW=
A549 NEPTZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjYTosyOOLCk{GwNOKhdk1? MV6yOE8{Pi92ODDo M2LUNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M3LacVI1PDh3N{m5
JJN3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vh[lI1NzR6IHi= MnK2SWM2ODxz4pEJcm08KDR64pEJbC=> M1jT[|I1ODNyMUWw
OPM-2 NGHQbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGyOE81QCCq MVXFR|Uxez1z4pEJcm08KDR64pEJbC=> NIDofWozPDB|MEG1NC=>
RPMI-8226 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHxUYQ4OjRxNEigbC=> MoDrSWM2OHN;MT645qCKdk19IES45qCKcA>? MXeyOFA{ODF3MB?=
U266 M2HTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK2NlQwPDhiaB?= MUDFR|Uxez1zMPMAjY5OQyB2OPMAjYg> MkPKNlQxOzBzNUC=
CA46 Mn2zRZBweHSxc3nzJGF{e2G7 M1H0UFYhcA>? NEGwVJBqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NEnlfFMzOzl4NkG2OC=>
DG75 Ml:0RZBweHSxc3nzJGF{e2G7 NH;SSFE3KGh? NH[5VmRqdmS3Y3XzJI5wKGGyb4D0c5Nqew>? MnXQNlM6PjZzNkS=
Ramos M2nmO2Fxd3C2b4Ppd{BCe3OjeR?= M{O4eFYhcA>? NXjaU5lFcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ MoDUNlM6PjZzNkS=
ST486 NI\NXI1CeG:ydH;zbZMhSXO|YYm= MXe2JIg> MUXpcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= NF7jNXEzOzl4NkG2OC=>
HuT78 NXTLZVVqSXCxcITvd4l{KEG|c3H5 MkH0NU8yOC9zMECgcm0> NWjqRnRFPDhiaB?= NGS3fHFqdmS3Y3XzJIFxd3C2b4Ppd{BifCBzIH7N NGXuO|czOzV|MkezNi=>
DpVp35 MlTCRZBweHSxc3nzJGF{e2G7 Mn[4NU8yOC9zMECgcm0> MoL5OFghcA>? M2PuPIlv\HWlZYOgZox2dnRiYYDvdJRwe2m| MmrUNlM2OzJ5M{K=
DpVp50 NXW2Zpd7SXCxcITvd4l{KEG|c3H5 M{\XUFEwOTBxMUCwJI5O MmrzOFghcA>? MYnpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NVvwb3VsOjN3M{K3N|I>
DpP75  NGnONotCeG:ydH;zbZMhSXO|YYm= Mo\GNU8yOC9zMECgcm0> Mn7UOFghcA>? Mmm0bY5lfWOnczDicJVvfCCjcH;weI9{cXN? MofhNlM2OzJ5M{K=
SKOV-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLTXVBUOeLCk{Kwcm0> MV:3NkBp MUfEUXNQ MXTy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> NWjnRZRMOjNyMUCzOFg>
Brca1 WT MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M174RlHjiJN{MH7N MkWwO|IhcA>? M170VWROW09? NHzJU4lz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NGTj[4czOzBzMEO0PC=>
Brca1 Null M1zEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK4Smky6oDVMkDuUS=> NHK1OW84OiCq MV\EUXNQ M33QdJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NYH3Sng5OjNyMUCzOFg>
OVCAR-8  NISyRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HzN|HjiJN{MH7N MmjLO|IhcA>? M4DqOWROW09? NXHldmxJemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MW[yN|AyODN2OB?=
NCI/ADR-RES M1XRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rsNFHjiJN{MH7N M4H2blczKGh? M2nSZmROW09? NVvVemlSemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MnTXNlMxOTB|NEi=
HCT116 NEKwcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[1JI5ONTVyIN88US=> M3q5dVI1KGh? NUHsOlA6TE2VTx?= NI\he41qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NYThN5NwOjJ7MkS5OVg>
RKO NG[1UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2raPFUhdk1vNUCg{txO NX\vTlhCOjRiaB?= NUfiN|JQTE2VTx?= MmC4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MlT0NlI6OjR7NUi=
CO115 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofjOUBvVS13MDFOwG0> MnL0NlQhcA>? MWjEUXNQ NX;oeFVNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NEDDWZEzOjl{NEm1PC=>
HFS M1PWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfBOUBvVQ>? NYXpfJNIOjRxNEivO|IhcA>? NVG4e3V7cW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? NV\6[ol6OjJzME[yPFI>
LNCaP MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGwOUBvVQ>? NIjMTWozPC92OD:3NkBp MkC0bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MV:yNlExPjJ6Mh?=
A549 NIjOfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPte3Q{PSCwTR?= MnK5NlQwPDhxN{KgbC=> NEewS2ZqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 Mlq2NlIyODZ{OEK=
697  M1vRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnsfWxKSzVy4pEJQgKBkTJwNdMgcm0> M3XpZ|IyPTN6MkG2
697-R MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe0b|ZKSzVy4pEJQgKBkThwNtMgcm3DqA>? MXOyNVU{QDJzNh?=
HUT78 M{\MWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFibl2= Mlj0NlEyQTh3NEW=
THJ-16T MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fISVEhdk1? NVvH[3FzOjRiaB?= MVvpcohq[mm2czDj[YxtKGe{b4f0bC=> NGfabY4zODhzMEW2PC=>
HCT116 MYTGeY5kfGmxbjDBd5NigQ>? NIC1PVYzOCCwTR?= NIK0VHY5KGh? NV3uSIl5dW:mdXzheIV{KHS{YX7zZ5JqeHRibHX2[Yx{KG[xcjDoeY5lemWmczDv[kBo\W6nczDpckBmcXSqZYKg[Ilz\WO2aX;u MkftNlA4Ozl2NUS=
B104  M17BZWZ2dmO2aX;uJGF{e2G7 MlWyNkBvVQ>? NEXnfIkzPC92OD:3NkBp NIPDcnlqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= NX75[II{OjB4OE[1NFU>
HL-60  MV3DfZRwfG:6aXPpeJkhSXO|YYm= MnvkNU02ODBibl2= NVfWZ5pQOjRiaB?= MoW3bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NYfHd2k{OjB4MkSxOlM>
HP100 NHTzXllEgXSxdH;4bYNqfHliQYPzZZk> M1;wU|EuPTByIH7N M3u1UlI1KGh? NYHxcWpFcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MX6yNFYzPDF4Mx?=
HL-60  NGPIZ21HfW6ldHnvckBCe3OjeR?= NUnJe25bOTBibl2= NWj2TFk3PC94L{G2JIg> MoPFbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq M{\WbVIxPjJ2MU[z
HP100 NXnEemxvTnWwY4Tpc44hSXO|YYm= NYjMeXM6OTBibl2= NYrGbpp6PC94L{G2JIg> MkLCbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq M1m2UVIxPjJ2MU[z
HL-60  NVi4WZJETnWwY4Tpc44hSXO|YYm= NX;nOVdHOTBvNUCwJI5O MVW0JIg> Mmfp[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi NFrwZ2UzODZ{NEG2Ny=>
HP100 M1L2PGZ2dmO2aX;uJGF{e2G7 MWCxNE02ODBibl2= NH;1WoY1KGh? MVjk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? MmGyNlA3OjRzNkO=
11z MofTT4lv[XOnIFHzd4F6 M{PGUlMuOTByIH7N NFTPOlNz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= MnfyNlA3ODVzNES=
SKOV-3 M2fHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LZSVQwQC9zNjDuUS=> NEDFPHg1QCCq NHjxbnpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NXW1OIozOjB2MES1OlQ>
OVCAR-3 M1rtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW0M|gwOTZibl2= MWO0PEBp M{nRUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MUKyNFQxPDV4NB?=
HBL-2 M1PEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[yNk0yOCCwTR?= MofpNlQhcA>? M{\0R2lEPTB;ND6zJI5O NHXYXHUzODB4OEC4NC=>
Jeko-1 NYnYTVdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyyMVUxKG6P MlXZNlQhcA>? MWLJR|UxRTFzIH7N NV;1d5dbOjByNkiwPFA>
Granta-519 NIfIbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC1MVQxKG6P M3PzcVI1KGh? MkCzTWM2OD13OD61JI5O MX:yNFA3QDB6MB?=
L1236 NFrkeWNEgXSxdH;4bYNqfHliQYPzZZk> MmjYNUBvVS1zMECg{txO MWi0PEBp NIXYXI5GSzVyPUCuNFch|ryP M1fMcVE6OjN|NEew
L428 M2XoVGN6fG:2b4jpZ4l1gSCDc4PhfS=> Mn;tNUBvVS1zMECg{txO M{joO|Q5KGh? NGDqOZhGSzVyPUCuOFMh|ryP M1HFUVE6OjN|NEew
KM-H2 MXXDfZRwfG:6aXPpeJkhSXO|YYm= NYjTR3Z1OSCwTT2xNFAh|ryP Mo\YOFghcA>? M2LsfWVEPTB;MD61PEDPxE1? NHXjS2kyQTJ|M{S3NC=>
L540Cy NGDRSHJEgXSxdH;4bYNqfHliQYPzZZk> NESyT2QyKG6PLUGwNEDPxE1? NFTtV3E1QCCq NGXYPIFGSzVyPUCuNVYh|ryP MnK1NVkzOzN2N{C=
G401 MlPwSpVv[3Srb36gRZN{[Xl? NFvyflcyOCCwTR?= NHfpU|EzPC92OD:3NkBp MXrEUXNQ MX7pcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NXXTfmltOTl{MkG1PFY>
STM91-01 NVfOSpNZTnWwY4Tpc44hSXO|YYm= NFfsU48yOCCwTR?= NGjaXJQzPC92OD:3NkBp NFLPSYNFVVOR NG[w[ppqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> M3fMR|E6OjJzNUi2
SJSC  M3;xUGZ2dmO2aX;uJGF{e2G7 NYryOJBQOTBibl2= NIfJeI0zPC92OD:3NkBp MWnEUXNQ NEnWW4FqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> Mmm4NVkzOjF3OE[=
BT16  Mlj0SpVv[3Srb36gRZN{[Xl? NV;FdllDOTBibl2= MmPlNlQwPDhxN{KgbC=> MXzEUXNQ MnjYbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NG[zUnEyQTJ{MUW4Oi=>
NCI-H1299 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\D[JhRUUN3ME20MlbDuTBwMjDu[{9udA>? MmfJNVkyPzl6OUC=
NCI-2882 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\ibm9KSzVyPUGuOuKyOC5yNDDu[{9udA>? MYSxPVE4QTh7MB?=
HCC95 M1jmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;vTWM2OD1{LkZCtVAvODVibnevcYw> NHL6UmkyQTF5OUi5NC=>
NCI-H23 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvwRnJKSzVyPUKuPeKyOC5{IH7nM41t NEnvTGMyQTF5OUi5NC=>
NCI-H157 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHLPFBKSzVyPUGuOuKyOC5yMjDu[{9udA>? NV3aUVM{OTlzN{m4PVA>
NCI-H460 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X6TmlEPTB;Mj6xxtExNjB5IH7nM41t NYLSOnhNOTlzN{m4PVA>
NCI-H1975 NXGyb4ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwM9MxNE4xPCCwZz;tcC=> MmnmNVkyPzl6OUC=
NCI-H820 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rnUWlEPTB;Mj60xtExNjFibnevcYw> MoTmNVkyPzl6OUC=
NCI-H1650 M1;PUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrSWZhwUUN3ME20MlnDuTBwMzDu[{9udA>? NU\E[YJROTlzN{m4PVA>
DTC1 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNUGgcm0> MYexPFU3PjJ2Nh?=
KAO NHzmNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwOUGgcm0> M1fFSVE5PTZ4MkS2
SU-CCS-1 NHSwNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwOEmgcm0> NUC1c3RmOTh3Nk[yOFY>
SYO-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPwcXVKSzVyPUCuOlchdk1? NHXsRmkyQDV4NkK0Oi=>
FUJI MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrtenh2UUN3ME2xMlMyKG6P MnrjNVg2PjZ{NE[=
SKNMC NEjGb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwMUegcm0> NFzzVXkyQDV4NkK0Oi=>
402-91 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLtTWM2OD1zLkK2JI5O MV:xPFU3PjJ2Nh?=
1765-92 NIi3S|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO4boNJUUN3ME2xMlc4KG6P MmLZNVg2PjZ{NE[=
JN-DSRCT-1 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjxRlR4UUN3ME2xMlI2KG6P M17KXVE5PTZ4MkS2
NMS-2PC NFrHUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli4TWM2OD1yLkixJI5O NH2xRlgyQDV4NkK0Oi=>
HL60 NYnMZm05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT0S4JxUUN3ME2xMlg3KG6P MYqxPFU3PjJ2Nh?=
A549 NFi2bJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTNwMkSgcm0> MUCxPFU3PjJ2Nh?=
SW480 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXnWVNKSzVyPUKuOlkhdk1? MkXGNVg2PjZ{NE[=
MCF7 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13vemlEPTB;Mz61OUBvVQ>? MWWxPFU3PjJ2Nh?=
PC-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\2VZplUUN3ME2yMlUyKG6P MUSxPFU3PjJ2Nh?=
MMRU MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y0eGlEPTB;Mj61O{BvVQ>? NEexdHIyQDV4NkK0Oi=>
Hs68 NWjSOVZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\DdWlEPTB;PkGwJI5O MXuxPFU3PjJ2Nh?=
hMSC-001F M{TtW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TPbGlEPTB;PkGwJI5O NEnoNnUyQDV4NkK0Oi=>

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01947140 Recruiting Lymphoid Malignancies|Multiple Myeloma|Lymphoma|Hodgkin Lymphoma|Non-hodgkin Lymphoma Jennifer Amengual|Columbia University September 9 2013 Phase 1|Phase 2
NCT02512497 Recruiting Cutaneous T-cell Lymphoma|T-Prolymphocytic Leukemia|T-Large Granulocytic Leukemia|T-Lymphoblastic Leukemia/Lymphoma|Peripheral T-Cell Lymphoma Ohio State University Comprehensive Cancer Center|Celgene Corporation December 8 2017 Phase 1
NCT00007345 Completed Cutaneous T Cell Lymphoma|Peripheral T Cell Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 8 2001 Phase 2
NCT00112463 Completed Adult Alveolar Soft-part Sarcoma|Adult Angiosarcoma|Adult Epithelioid Sarcoma|Adult Extraskeletal Chondrosarcoma|Adult Extraskeletal Osteosarcoma|Adult Fibrosarcoma|Adult Leiomyosarcoma|Adult Liposarcoma|Adult Malignant Fibrous Histiocytoma|Adult Malignant Hemangiopericytoma|Adult Malignant Mesenchymoma|Adult Neurofibrosarcoma|Adult Rhabdomyosarcoma|Adult Synovial Sarcoma|Gastrointestinal Stromal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Adult Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma National Cancer Institute (NCI) January 7 2005 Phase 2
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital January 6 2017 Phase 2
NCT02181218 Recruiting Lymphoma T-Cell Cutaneous|Lymphoma T-Cell Peripheral|Hodgkin Disease|Lymphoma Large B-Cell Diffuse Washington University School of Medicine|Celgene February 4 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID